JP2011173928A5 - - Google Patents

Download PDF

Info

Publication number
JP2011173928A5
JP2011173928A5 JP2011128592A JP2011128592A JP2011173928A5 JP 2011173928 A5 JP2011173928 A5 JP 2011173928A5 JP 2011128592 A JP2011128592 A JP 2011128592A JP 2011128592 A JP2011128592 A JP 2011128592A JP 2011173928 A5 JP2011173928 A5 JP 2011173928A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
dose
epothilone
pharmaceutical formulation
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011128592A
Other languages
English (en)
Other versions
JP2011173928A (ja
Filing date
Publication date
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from US09/233,993 external-priority patent/US6302838B1/en
Application filed filed Critical
Publication of JP2011173928A publication Critical patent/JP2011173928A/ja
Publication of JP2011173928A5 publication Critical patent/JP2011173928A5/ja
Pending legal-status Critical Current

Links

Claims (7)

  1. 有効成分としてエポチロンＢを含む増殖性疾患の処置のための医薬製剤であって、
    増殖性疾患を有する対象に対して、１回の投与から次の投与までが１〜６週間の間隔で、各時点につき０.３〜７.５mg／ｍ ２ の投与量で、１８〜２４日毎に、
    式：１回量(mg／ｍ ２ )＝(０.１〜６)×Ｎ
    (式中、Ｎは１回の投与から次の投与までの週の数)
    に従って計算される投与量で投与される
    ことを特徴とする、医薬製剤。
  2. 投与量が最大耐量（ＭＴＤ）の２５から１００％である、請求項１に記載の医薬製剤。
  3. 投与が静脈内点滴によって行われる、請求項１または２に記載の医薬製剤。
  4. 各静脈内点滴が５〜３０分かけて行われる、請求項３に記載の医薬製剤。
  5. 増殖性疾患がエポチロン以外の１種またはそれ以上の化学療法薬処置に不応性（refractory）である、請求項１〜４のいずれかに記載の医薬製剤。
  6. 任意の他の抗腫瘍治療薬との組み合わせで投与される、請求項１〜５のいずれかに記載の医薬製剤。
  7. 請求項１〜６のいずれかに記載の医薬製剤を製造するための、エポチロンＢの使用。
JP2011128592A 1998-02-25 2011-06-08 癌処置のためのエポチロンの使用 Pending JP2011173928A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GB9803907.6 1998-02-25
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GB9803905.0 1998-02-25
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
GB9805936.3 1998-03-19
GB9805937.1 1998-03-19
US09/233,993 1999-01-19
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000533117A Division JP2002504511A (ja) 1998-02-25 1999-02-23 癌処置のためのエポチロンの使用

Publications (2)

Publication Number Publication Date
JP2011173928A JP2011173928A (ja) 2011-09-08
JP2011173928A5 true JP2011173928A5 (ja) 2012-07-26

Family

ID=27451759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011128592A Pending JP2011173928A (ja) 1998-02-25 2011-06-08 癌処置のためのエポチロンの使用

Country Status (4)

Country Link
US (1) US6302838B1 (ja)
JP (1) JP2011173928A (ja)
AT (1) ATE483462T1 (ja)
DE (1) DE69942827D1 (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
MXPA03007729A (es) * 2001-02-27 2003-12-04 Novartis Ag Combinacion que comprende un inhibidor de transduccion de senal y un derivado de epotilona.
MXPA03008462A (es) * 2001-03-19 2003-12-08 Novartis Ag Combinaciones que comprenden un agente antidiarreico y una epotilona o un derivado de epotilona.
US20070203346A1 (en) * 2001-04-30 2007-08-30 Oregon State University Method for synthesizing epothilones and epothilone analogs
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
IL162595A0 (en) * 2002-01-14 2005-11-20 Novartis Ag Combinations comprising epothilones and antimetabolites
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
PL211114B1 (pl) * 2002-05-01 2012-04-30 Novartis Ag Zastosowanie pochodnej epotilonowej w leczeniu choroby nowotworowej
AU2003296878A1 (en) * 2002-05-20 2004-12-13 Kosan Biosciences, Inc. Methods to administer epothilone d
ES2281692T3 (es) 2002-08-23 2007-10-01 Sloan-Kettering Institute For Cancer Research Sintesis de epotilones, sus intermediarios, sus analogos y sus usos.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1553938T3 (da) * 2002-10-15 2007-03-26 Univ Louisiana State Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
EP2251343A1 (en) * 2003-05-15 2010-11-17 Arqule, Inc. Imidazothiazoles as p38-kinase-inhibitors
US20060205795A1 (en) * 2003-06-27 2006-09-14 David Parkinson Cancer treatment with epothilones
EP1663214A1 (en) * 2003-09-02 2006-06-07 Novartis AG Cancer treatment with epothilones
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
WO2006010082A1 (en) * 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
JP2008517064A (ja) * 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
SI2450437T1 (sl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc. Okvarjenost genov in mutantna ALK kinaza v človeških solidnih tumorjih
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
JP5419685B2 (ja) 2006-05-16 2014-02-19 ファーマサイエンス・インコーポレイテッド Ｉａｐｂｉｒドメイン結合タンパク質
WO2010065893A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
WO2010108934A1 (en) * 2009-03-25 2010-09-30 Novartis Ag Pharmaceutical composition containing a drug and sirna
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
WO2011146638A1 (en) 2010-05-18 2011-11-24 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.

Similar Documents

Publication Publication Date Title
JP2011173928A5 (ja)
CA2856646C (en) Combination treatment of cancer
JP2014515373A5 (ja)
JP2009102342A5 (ja)
JP2018513188A5 (ja)
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
JP2015512406A5 (ja)
MX2012007410A (es) Compuestos antivirales novedosos.
JP2013067645A5 (ja)
JP2012180381A5 (ja)
JP2014526503A5 (ja)
JP2012193216A5 (ja)
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
NZ711179A (en) Oral formulations of deferasirox
JP2010521417A5 (ja)
JP2015522630A5 (ja)
JP2010526101A5 (ja)
JP2013541583A5 (ja)
JP2013209384A5 (ja)
JP2017132791A (ja) 組み合わせ組成物
JP2013516493A5 (ja)
JP2019218379A5 (ja)
JP2015522033A5 (ja)
JP2019507786A5 (ja)
JP2020510043A5 (ja)